• Actinium Pharmaceuticals will present its first-in-human Phase 1 ATNM-400 study at ESMO in Madrid, Oct. 23-27, 2026.
• The trial evaluates the HER3-targeted radiotherapy in metastatic castration-resistant prostate cancer, including patients with or without prior PSMA-directed treatment.
• Initial imaging results already presented at EANM showed tumor retention, with encouraging tolerability.
• The study will assess safety to establish a recommended Phase 2 dose, with additional evaluation of antitumor activity.
• The prostate cancer trial is the first clinical step in a strategy to expand ATNM-400 into additional solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610230800PR_NEWS_USPR_____NY79485) on October 23, 2026, and is solely responsible for the information contained therein.